摘要
目的 :比较瑞格列奈(Repaglinide)联合生物合成中效人胰岛素(NPH)睡前注射治疗和单用二甲双胍治疗 ,对磺脲类药物(SU)控制不佳的2型糖尿病(T2DM)患者的疗效、安全性及对胰岛β 细胞功能的影响。方法 :观察组用瑞格列奈联合NPH睡前注射治疗 ,对照组用二甲双胍治疗 ,疗程均为12周 ,观察治疗前后的空腹血糖(FBG)、餐后2h血糖(P2BG)、糖化血红蛋白(HbA1c)、体重指数(BMI)、空腹C肽(FCP)及餐后2hC肽(P2CP)分泌水平。结果 :12周后 ,观察组的FBG ,P2BG ,HbA1c明显下降(均P<0 .01) ,FCP明显升高(P<0 .05) ,P2CP变化无统计学意义。同对照组相比FBG ,P2BG ,HbA1c,FCP等指标的改善有较显著差异(均P<0.01)。对照组治疗前后比较 ,FBG ,BMI下降明显(均P<0 .05) ,P2BG ,HbA1c ,FCP ,P2CP变化无统计学意义。结论 :瑞格列奈联合NPH治疗方案适合于T2DM对SU疗效不佳者 ,且对胰岛 β细胞功能有改善 。
Objective:To clinically observe the effect of repaglinide(NovoNorn)combined with NPH(Novolin N)on type2diabetes mellitus(T2DM)patients who did not react well to sulphonylurea drugs.Methods:Treatˉment group(n=27)was treated with repaglinide combined with NPH,while control group(n=27)was treated with metformin.The levels of the fasting blood glucose(FBG),the postprandial2ˉhour blood glucose(P2BG),HbA 1 c,the fasting Cˉpeptide(FCP),the postprandial2ˉhour blood Cˉpeptide(P2CP)and the body mass index(BMI)were measured at baseline and at the end of12ˉweek active treatment period.Results:In the treatment group,the levels of FBG,P2BG,HbA 1 c at the end were obviously lower than those at baseline(all P<0.01)and the level of FCP at the end was higher than that at baseline(P<0.05).No significant change was seen in the levels of P2CP or BMI.At the end,the levels of FBG,P2BG,HbA 1 c in the treatment group were lower than those in the control group and the level of FCP in the treatment group were higher than that in the control group(all P<0.01).In the control group,the levels of FBG and BMI at the end lower than those at baseline(all P<0.05).Conclusion:The affects,the securities and the preventions for pancreaticβˉcell function of repaglinide(NovoNorn)combined with NPH(Novolin N)were better than those of metformin in T2DM patients who did not well react to sulphonylurea drugs.
出处
《天津医药》
CAS
北大核心
2003年第5期294-296,共3页
Tianjin Medical Journal
